Researchers have identified a novel biomarker of schizophrenia in humans that studies in mice suggest could also function as a new drug candidate. The biomarker discovery represents a potential dual advance in both diagnosis and treatment of the psychiatric disorder.
Mouse studies indicated the biomarker could serve as a therapeutic target to correct overexcited brain circuits associated with schizophrenia. The research focused specifically on addressing cognitive symptoms of the disorder, which remain difficult to treat with current medications.